DK2954779T3 - Mus, der frembringer tungkædeantistoffer - Google Patents

Mus, der frembringer tungkædeantistoffer Download PDF

Info

Publication number
DK2954779T3
DK2954779T3 DK15177538.4T DK15177538T DK2954779T3 DK 2954779 T3 DK2954779 T3 DK 2954779T3 DK 15177538 T DK15177538 T DK 15177538T DK 2954779 T3 DK2954779 T3 DK 2954779T3
Authority
DK
Denmark
Prior art keywords
mice
heavy chain
chain antibodies
produce heavy
produce
Prior art date
Application number
DK15177538.4T
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2954779T3 publication Critical patent/DK2954779T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15177538.4T 2009-12-10 2010-12-10 Mus, der frembringer tungkædeantistoffer DK2954779T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28525009P 2009-12-10 2009-12-10
EP10790825.3A EP2509409B1 (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Publications (1)

Publication Number Publication Date
DK2954779T3 true DK2954779T3 (da) 2019-05-13

Family

ID=43534479

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10790825.3T DK2509409T3 (da) 2009-12-10 2010-12-10 Mus, der producerer tungkædeantistoffer
DK15177538.4T DK2954779T3 (da) 2009-12-10 2010-12-10 Mus, der frembringer tungkædeantistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10790825.3T DK2509409T3 (da) 2009-12-10 2010-12-10 Mus, der producerer tungkædeantistoffer

Country Status (24)

Country Link
US (9) US8754287B2 (da)
EP (3) EP2954779B1 (da)
JP (5) JP5909449B2 (da)
KR (2) KR101430514B1 (da)
CN (3) CN104131035A (da)
AU (1) AU2010328046C1 (da)
CA (1) CA2782936C (da)
CY (2) CY1118163T1 (da)
DK (2) DK2509409T3 (da)
ES (2) ES2595376T3 (da)
HK (2) HK1177100A1 (da)
HR (1) HRP20190820T1 (da)
HU (2) HUE030208T2 (da)
IL (4) IL220150A0 (da)
LT (2) LT2509409T (da)
MY (2) MY173363A (da)
PL (2) PL2954779T3 (da)
PT (2) PT2954779T (da)
RS (1) RS58709B1 (da)
RU (1) RU2603102C2 (da)
SG (2) SG181477A1 (da)
SI (2) SI2509409T1 (da)
TR (1) TR201906488T4 (da)
WO (1) WO2011072204A1 (da)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101457753B1 (ko) 2004-07-22 2014-11-03 에라스무스 유니버시티 메디컬 센터 로테르담 결합 분자
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
SG181477A1 (en) * 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2728942T3 (es) 2010-02-08 2019-10-29 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR101830020B1 (ko) 2010-03-31 2018-02-19 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
PL2738258T5 (pl) 2011-02-25 2023-05-15 Regeneron Pharmaceuticals, Inc. Myszy adam6
EP2683735A1 (en) * 2011-03-10 2014-01-15 HCO Antibody, Inc. Bispecific three-chain antibody-like molecules
SG10201914002RA (en) 2011-08-05 2020-03-30 Regeneron Pharma Humanized universal light chain mice
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN108200885B (zh) 2011-10-17 2021-12-14 瑞泽恩制药公司 受限制的免疫球蛋白重链基因座
WO2013082463A2 (en) * 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-fu
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
AU2012323987B2 (en) 2011-12-20 2015-07-09 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
RS59076B1 (sr) 2012-03-16 2019-09-30 Regeneron Pharma Glodari koji eksprimiraju imunoglobulinske sekvence senzitivne na ph
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
NZ629639A (en) 2012-03-16 2017-03-31 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP2831245A1 (en) * 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
LT2858487T (lt) 2012-06-12 2019-12-27 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, kurie yra humanizuoti ir turi redukuotą imunoglobulino sunkiosios grandinės lokusą
AU2014218915B2 (en) * 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
DK2958937T3 (da) * 2013-02-22 2018-11-26 Regeneron Pharma Mus, der eksprimerer humaniseret major histokompatibilitetskompleks
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
ES2839087T3 (es) * 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
CN106163273B (zh) * 2014-04-08 2020-07-24 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
IL251010B2 (en) 2014-10-22 2024-01-01 Crescendo Biologics Ltd transgenic mice
PT3221363T (pt) 2014-11-21 2020-07-23 Bristol Myers Squibb Co Anticorpos contra cd73 e utilizações dos mesmos
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
US20180237534A1 (en) 2015-05-29 2018-08-23 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108138200A (zh) * 2015-08-24 2018-06-08 特里安尼公司 增强的免疫球蛋白产生
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EA201891925A1 (ru) 2016-03-04 2019-02-28 Зэ Рокфеллер Юниверсити Антитела к cd40 с усиленной агонистической активностью
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017184942A1 (en) * 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
SG11201809793UA (en) 2016-05-09 2018-12-28 Bristol Myers Squibb Co Tl1a antibodies and uses thereof
KR102356542B1 (ko) 2016-05-20 2022-01-28 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyl transferase
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP2020500007A (ja) 2016-10-13 2020-01-09 マサチューセッツ インスティテュート オブ テクノロジー ジカウイルスエンベロープタンパク質に結合する抗体およびその使用
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018290882B2 (en) 2017-06-27 2023-07-27 Regeneron Pharmaceuticals, Inc. Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
KR20200021987A (ko) 2017-06-27 2020-03-02 리제너론 파마슈티칼스 인코포레이티드 유전 물질을 인간 세포 내로 표적화하여 도입하기 위한 향성-변형 재조합 바이러스 입자 및 이의 용도
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
JP6677277B2 (ja) 2017-07-19 2020-04-08 株式会社デンソー 車両用制御装置及び電源供給回路
AU2018302343B2 (en) 2017-07-21 2020-11-26 Trianni, Inc. Single chain vh and heavy chain antibodies
TW201930350A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｐｄ－ｌ１之抗體及其變異體
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
KR20200120641A (ko) 2018-01-15 2020-10-21 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
CN116420679A (zh) * 2018-03-26 2023-07-14 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
CA3101859A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
AU2019284256A1 (en) * 2018-06-13 2020-12-24 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
LT3629720T (lt) 2018-06-14 2022-03-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
SG11202112917PA (en) 2019-05-24 2021-12-30 Regeneron Pharma Modified viral particles and uses thereof
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN115066440A (zh) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
WO2021170071A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
CN111333719B (zh) * 2020-03-16 2021-10-01 西南大学 抗hpv16e7蛋白单抗69a6、杂交瘤细胞及其制备方法和应用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CA3185858A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
BR112022026508A2 (pt) * 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
JP2023536461A (ja) 2020-07-29 2023-08-25 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
JP2024500251A (ja) 2020-12-09 2024-01-05 トリアンニ，インコーポレーテッド 重鎖のみ抗体
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
KR20220118962A (ko) 2021-02-19 2022-08-26 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
BR112023016717A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47, molécula de ácido nucleico, e, uso do anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47
BR112023016713A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
EP4333614A1 (en) * 2021-05-05 2024-03-13 Leveragen, Inc. Engineered non-human animals for producing antibodies
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
CA3224182A1 (en) * 2021-06-17 2022-12-22 Fapon Biotech Inc. Chimeric immunoglobulin
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
CA3233698A1 (en) 2021-11-04 2023-05-11 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to skeletal muscle
WO2023164581A2 (en) * 2022-02-24 2023-08-31 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024056044A1 (en) * 2022-09-16 2024-03-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals and methods for producing heavy-chain antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
AU781922B2 (en) * 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1498427E (pt) * 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6838254B1 (en) * 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6080910A (en) * 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP1575499A2 (en) * 2002-06-28 2005-09-21 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
US7534604B2 (en) 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
KR101457753B1 (ko) * 2004-07-22 2014-11-03 에라스무스 유니버시티 메디컬 센터 로테르담 결합 분자
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
WO2006117699A2 (en) 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
BRPI0706750A2 (pt) * 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
PT2005185E (pt) * 2006-03-22 2011-01-27 Viral Logic Systems Technology Corp Métodos para a identificação de alvos polipeptídicos
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
PT2152880E (pt) 2007-06-01 2011-12-15 Omt Inc Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos
BRPI0812465A2 (pt) * 2007-06-08 2014-12-02 Dow Global Technologies Inc Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
MX2010002044A (es) 2007-09-07 2010-03-18 Symphogen As Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv).
WO2009114400A1 (en) 2008-03-07 2009-09-17 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20100122358A1 (en) * 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
SG181477A1 (en) * 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
JP6023667B2 (ja) * 2013-06-26 2016-11-09 矢崎総業株式会社 コネクタ
JP5602929B1 (ja) * 2013-11-08 2014-10-08 株式会社小松製作所 モータグレーダのリッパー装置およびこれを備えたモータグレーダ

Also Published As

Publication number Publication date
CA2782936C (en) 2019-06-18
IL257822B (en) 2020-01-30
JP2017140058A (ja) 2017-08-17
HK1220865A1 (zh) 2017-05-19
CY1121608T1 (el) 2020-05-29
CY1118163T1 (el) 2017-06-28
ES2724975T3 (es) 2019-09-18
PT2509409T (pt) 2016-09-29
HRP20190820T1 (hr) 2019-09-20
RU2012128856A (ru) 2014-01-20
CN110079550A (zh) 2019-08-02
CN102711449B (zh) 2015-01-07
LT2954779T (lt) 2019-05-27
US20150196015A1 (en) 2015-07-16
KR20130055556A (ko) 2013-05-28
IL237819A (en) 2017-03-30
US20110145937A1 (en) 2011-06-16
CN104131035A (zh) 2014-11-05
JP6615830B2 (ja) 2019-12-04
US20150197555A1 (en) 2015-07-16
IL257822A (en) 2018-04-30
SI2509409T1 (sl) 2016-12-30
IL220150A0 (en) 2012-07-31
PL2509409T3 (pl) 2017-02-28
JP2015077147A (ja) 2015-04-23
HUE043556T2 (hu) 2019-09-30
SI2954779T1 (sl) 2019-06-28
LT2509409T (lt) 2016-12-12
DK2509409T3 (da) 2016-11-14
KR101553244B1 (ko) 2015-09-15
PT2954779T (pt) 2019-05-29
KR101430514B1 (ko) 2014-08-19
AU2010328046C1 (en) 2018-01-18
JP6293702B2 (ja) 2018-03-14
TR201906488T4 (tr) 2019-05-21
EP2954779A1 (en) 2015-12-16
ES2595376T3 (es) 2016-12-29
AU2010328046B2 (en) 2014-07-31
JP2015133991A (ja) 2015-07-27
PL2954779T3 (pl) 2019-07-31
KR20140024970A (ko) 2014-03-03
US20140289876A1 (en) 2014-09-25
AU2010328046A1 (en) 2012-07-12
CA2782936A1 (en) 2011-06-16
SG10201408181PA (en) 2015-01-29
HK1177100A1 (en) 2013-08-16
EP2954779B1 (en) 2019-02-06
EP3504964A1 (en) 2019-07-03
JP5909449B2 (ja) 2016-04-26
US11234419B2 (en) 2022-02-01
SG181477A1 (en) 2012-07-30
MY173363A (en) 2020-01-21
US20150197556A1 (en) 2015-07-16
HUE030208T2 (en) 2017-04-28
US20150197553A1 (en) 2015-07-16
EP2509409A1 (en) 2012-10-17
IL237818A (en) 2016-08-31
JP6271450B2 (ja) 2018-01-31
EP2509409B1 (en) 2016-07-27
JP2013513388A (ja) 2013-04-22
US9888675B2 (en) 2018-02-13
US8754287B2 (en) 2014-06-17
RU2603102C2 (ru) 2016-11-20
JP2019141095A (ja) 2019-08-29
US20150197557A1 (en) 2015-07-16
CN102711449A (zh) 2012-10-03
US20220201993A1 (en) 2022-06-30
RS58709B1 (sr) 2019-06-28
MY172472A (en) 2019-11-26
WO2011072204A1 (en) 2011-06-16
US20150197554A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
DK2954779T3 (da) Mus, der frembringer tungkædeantistoffer
BRPI1012694A2 (pt) anticorpos solúveis apenas com cadeia pesada
SMT201700083B (it) Anticorpi monoclonali
BR112012030311A2 (pt) anticorpo
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI1009789A2 (pt) desacoplador.
BRPI1014474A2 (pt) anticorpos biespecíficos anti-erbb-1/anti-c-met.
BRPI1008949A2 (pt) Cetoenóis haloalquilmetilenóxi-fenil-substituídos.
BRPI0919841A2 (pt) Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
DE10767394T8 (de) Kindertrage
BRPI1006417A2 (pt) transportador convergente
CO6791565A2 (es) Anticuerpos anti-notch1
IT1397957B1 (it) Pedana vibrante.
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI1015957A2 (pt) Lanche impregnado de sabor de castanha
IT1396487B1 (it) Convogliatore.
NO20093389A (no) Lyddemper
BR112012002612A2 (pt) calha.
BRPI0912769A2 (pt) anticorpos anti-pirb
BRPI0922477A2 (pt) transportador.
IT1401589B1 (it) Zeoliti ad azione neuroprotettiva.
IT1401345B1 (it) Bomboletta.
ITTO20110675A1 (it) Motociclo.
FI20096331A0 (fi) Antibodin käyttö